<DOC>
	<DOC>NCT00807118</DOC>
	<brief_summary>Primary objectives are to demonstrate bioequivalence between 4 and 8 mg of commercial formulation in both under fasted and fed condition, and bioequivalence between formulation E(1) used in Japanese pivotal study and commercial formulation in 8 mg. Secondary objective is to assess food effect on 8 mg tablet of commercial formulation. These objectives are set to get data for Japanese regulatory submission.</brief_summary>
	<brief_title>Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect</brief_title>
	<detailed_description />
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Japanese healthy male subject Evidence or history of clinically significant findings at screening</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>bioequivalence, food effect</keyword>
</DOC>